skip to Main Content
NEWS

Press Release

NEWS

NEWS

Release Summary

We believe that the products will fast become the standard of effectiveness and ease of use when it comes to bone graft substitutes in 2018.

More News
Biogennix Ramps Up National Distribution for Bone Graft Substitute Products osteoSPAN and Morpheus
read more
Biogennix Bone Graft Substitute Materials Used to Treat 6000th Patient
read more
Biogennix Reports Record Growth for 2017; Expands Executive Management Team
read more
Contacts

Medialine Communications, 310-569-0023
paul@medialinecommunications.com

May 15, 2018 11:35 AM Eastern Standard Time

IRVINE, Calif. — May 15, 2018 — Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures, announced today that it saw 33% growth for the first quarter of 2018, marking the company’s strongest quarter yet. This news follows on the heels of Biogennix’s record growth for 2017.

“The momentum we had coming into 2018 after a record year last year continues to mount,” said Scott Bauccio, Biogennix’s Vice President of Sales and Business Development. “Our Morpheus and osteoSPAN bone graft products fueled the 33% growth we saw in Q1 and we’re on a pace to replicate that success once again with our Q2 numbers. These products are fast becoming the new standard of effectiveness and ease of use in the bone graft substitute space.”

The majority of Biogennix’s steady growth is attributed to increases in sales of the company’s novel bone graft substitutes, Morpheus and osteoSPAN, both of which are resorbable, osteoconductive scaffolds ideally suited for bone regeneration.  The Morpheus product is a moldable version of osteoSPAN, which combines the granules with an organic binder, providing optimal handling characteristics for surgeons.

Biogennix is a leading developer of osteobiologic products specifically designed for posterolateral spine  and long bone fusion. The company is led by a team of scientists and industry veterans committed to delivering unique products for bone regeneration. Biogennix designs, manufactures and distributes all of its products from its Irvine facilities.

Biogennix is a fully-integrated osteobiologic company headquartered in Irvine which develops, manufactures, and distributes proprietary bone graft substitutes used in bone fusion procedures. Learn more at biogennix.com.

Contacts for Biogennix
Medialine, 310-569-0023
paul@medialinecommunications.com

Back To Top
×Close search
Search